Abstract
Several lines of evidence suggest that the cyclooxygenase enzymes (specifically COX-2) might be an important molecular target for the intervention of cancer at both early and late stages of some cancers, providing an opportunity for both cancer prevention and therapy. COX-2 is overexpressed during carcinogenesis, and appears to have a role in both tumour initiation and promotion and is amenable to intervention. This review discusses the importance of COX modulation via non-specific, as well as COX-2 specific COX inhibitors (NSAIDs and COX-2 selective inhibitors [COXIB]). A brief discussion on the pharmacoeconomic considerations of NSAID and COXIB use and safety issues that have recently been the focus of debate, will be presented.
Original language | English (US) |
---|---|
Pages (from-to) | 2193-2204 |
Number of pages | 12 |
Journal | Expert opinion on pharmacotherapy |
Volume | 4 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2003 |
Externally published | Yes |
Keywords
- Cancer prevention
- Cancer treatment
- Cyclooxygenase inhibition
- Cyclooxygenase overexpression
- Nonsteroidal anti-inflammatory drugs
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)